XFRA CAPITAL ADJUSTMENT INFORMATION

XFRA CAPITAL ADJUSTMENT INFORMATION - 28.09.2023

Das Instrument 7AC SE0009268717 ACARIX AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.09.2023 und ex Kapitalmassnahme am 29.09.2023
The instrument 7AC SE0009268717 ACARIX AB EQUITY is traded cum capital adjustment on 28.09.2023 and ex capital adjustment on 29.09.2023

Das Instrument 8IN US87166B1026 SYNEOS HEALTH A DL-,01 EQUITY wird cum Kapitalmassnahme gehandelt am 28.09.2023 und ex Kapitalmassnahme am 29.09.2023
The instrument 8IN US87166B1026 SYNEOS HEALTH A DL-,01 EQUITY is traded cum capital adjustment on 28.09.2023 and ex capital adjustment on 29.09.2023

Das Instrument UF7N SG1AI1000008 GOLDEN ENERGY+RES SD-,10 EQUITY wird ex Kapitalmassnahme gehandelt am 28.09.2023
The instrument UF7N SG1AI1000008 GOLDEN ENERGY+RES SD-,10 EQUITY is traded ex capital adjustment on 28.09.2023

Das Instrument CBSX IE00BG5J1M21 HANETF-MED.CANN+WELL.DL A ETF wird cum Kapitalmassnahme gehandelt am 28.09.2023 und ex Kapitalmassnahme am 29.09.2023
The instrument CBSX IE00BG5J1M21 HANETF-MED.CANN+WELL.DL A ETF is traded cum capital adjustment on 28.09.2023 and ex capital adjustment on 29.09.2023

Das Instrument HHU GB00B02LCQ05 ALLERGY THER. PLC LS-,001 EQUITY wird ex Kapitalmassnahme gehandelt am 28.09.2023
The instrument HHU GB00B02LCQ05 ALLERGY THER. PLC LS-,001 EQUITY is traded ex capital adjustment on 28.09.2023

Großer Insider-Report 2024 von Dr. Dennis Riedl

Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.

Hier klicken

Zeit	Aktuelle Nachrichten
14.11.23	Nasdaq Stockholm AB: New equity right for trading, Acarix AB TO2 and Acarix AB TO3 (575/23)	At the request of Acarix AB, Acarix AB equity rights will be traded on First North Growth Market as from November, 15, 2023. Security name: ACARIX 2024:U1 (TO2) ------------------------------------ Short... ► Artikel lesen
08.11.23	Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Acarix AB (565/23)	Trading in Acarix paid subscription units is to cease. The last trading day is November 9, 2023. Short name: Acarix BTU ISIN code: SE0020996866 Orderbook ID: 306928 This information is distributed... ► Artikel lesen
28.09.23	XFRA CAPITAL ADJUSTMENT INFORMATION - 28.09.2023	Das Instrument 7AC SE0009268717 ACARIX AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.09.2023 und ex Kapitalmassnahme am 29.09.2023 The instrument 7AC SE0009268717 ACARIX AB EQUITY is traded cum... ► Artikel lesen

Zeit

Aktuelle Nachrichten

14.11.23

Nasdaq Stockholm AB: New equity right for trading, Acarix AB TO2 and Acarix AB TO3 (575/23)

At the request of Acarix AB, Acarix AB equity rights will be traded on First North Growth Market as from November, 15, 2023. Security name: ACARIX 2024:U1 (TO2) ------------------------------------ Short...
► Artikel lesen

08.11.23

Nasdaq Stockholm AB: Last day of trading in paid subscription units (BTU) of Acarix AB (565/23)

Trading in Acarix paid subscription units is to cease. The last trading day is November 9, 2023. Short name: Acarix BTU ISIN code: SE0020996866 Orderbook ID: 306928 This information is distributed...
► Artikel lesen

28.09.23

XFRA CAPITAL ADJUSTMENT INFORMATION - 28.09.2023

Zeit	Aktuelle Nachrichten
03.04.	Allergy Therapeutics - Director Resignation
27.03.	Allergy Therapeutics - Update on funding
27.03.	Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023
12.03.	Allergy Therapeutics starts dosing patients in peanut allergy trial
12.03.	Allergy Therapeutics - VLP Peanut PROTECT Trial Update

Zeit

Aktuelle Nachrichten

03.04.

Allergy Therapeutics - Director Resignation

27.03.

Allergy Therapeutics - Update on funding

27.03.

Allergy Therapeutics - Interim Results for six months ended 31 Dec 2023

12.03.

Allergy Therapeutics starts dosing patients in peanut allergy trial

12.03.

Allergy Therapeutics - VLP Peanut PROTECT Trial Update

Zeit	Aktuelle Nachrichten
28.09.23	XFRA CAPITAL ADJUSTMENT INFORMATION - 28.09.2023		Das Instrument 7AC SE0009268717 ACARIX AB EQUITY wird cum Kapitalmassnahme gehandelt am 28.09.2023 und ex Kapitalmassnahme am 29.09.2023 The instrument 7AC SE0009268717 ACARIX AB EQUITY is traded cum... ► Artikel lesen

Zeit

Aktuelle Nachrichten

28.09.23

XFRA CAPITAL ADJUSTMENT INFORMATION - 28.09.2023

Zeit	Aktuelle Nachrichten
22.03.	Research and Markets: 2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report Featuring IQVIA, ICON, Parexel, Fortrea (formerly Labcorp), PPD/Thermo Fisher, and Syneos Health - ResearchAndMarkets.com	The "2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report" has been added to ResearchAndMarkets.com's offering. The biopharmaceutical clinical development landscape... ► Artikel lesen
08.02.	Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2024 Results	Reports 18.3% Revenue Increase and ARR of $15.6 Million HENDERSON, Nev., Feb. 8, 2024 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), a trusted partner providing cloud-based workflow... ► Artikel lesen
04.01.	Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE	Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®... ► Artikel lesen
27.11.23	Research Solutions, Inc.: Research Solutions Announces Acquisition of scite	Transforms Search and Discovery Solutions for Researchers by Delivering Breakthrough AI Technology Adds $3.6 Million in Annualized Software Subscription Revenue HENDERSON, Nev.... ► Artikel lesen
16.11.23	Odyssey Health Selects Syneos to Support Concussion Treatment Trial

Zeit

Aktuelle Nachrichten

22.03.

Research and Markets: 2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report Featuring IQVIA, ICON, Parexel, Fortrea (formerly Labcorp), PPD/Thermo Fisher, and Syneos Health - ResearchAndMarkets.com

The "2024 Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report" has been added to ResearchAndMarkets.com's offering. The biopharmaceutical clinical development landscape...
► Artikel lesen

08.02.

Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2024 Results

Reports 18.3% Revenue Increase and ARR of $15.6 Million HENDERSON, Nev., Feb. 8, 2024 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), a trusted partner providing cloud-based workflow...
► Artikel lesen

04.01.

Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE

Press Release Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® Crossject expanding market access activities in preparation for filing for marketing authorization ZEPIZURE®...
► Artikel lesen

27.11.23

Research Solutions, Inc.: Research Solutions Announces Acquisition of scite

Transforms Search and Discovery Solutions for Researchers by Delivering Breakthrough AI Technology Adds $3.6 Million in Annualized Software Subscription Revenue HENDERSON, Nev....
► Artikel lesen

16.11.23

Odyssey Health Selects Syneos to Support Concussion Treatment Trial